Bildkälla: Stockfoto

Xintela: Awaiting results in trials and discussions - VH Corp

• Clinical studies progressing as planned

• A loan of MSEK 16.5 granted by Flerie Invest

• We keep the fair value at SEK 1.30 per share

During Q4 2023, Xintela's project progressed according to plan. To meet the
short-term capital requirement, the company raised a loan of SEK 16.5 million
from Flerie Invest, Xintela's main owner. This satisfies the immediate capital
need, but the company must find a medium-term financing plan. We therefore see
a significant financial risk in the company.

Xintela reported a negative cash flow of SEK 11.6 million for the quarter and
had a cash balance of SEK 7.8 million at the end of the year. Despite the
financial situation, we still see great potential in the company and our
motivated value is significantly higher than the current market value. Recent
developments have not significantly changed our risk assumptions from our
first report published in December 2023.

We therefore maintain our risk-adjusted motivated value of SEK 1.30 per share.
Börsvärldens nyhetsbrev
ANNONSER